Virtual Library

 x 
My Library Virtual Library FAQ

Start Your Search

H. Imai



Author of

  • +

    P1.07 - Poster Session with Presenters Present (ID 459)

    • Event: WCLC 2016
    • Type: Poster Presenters Present
    • Track: SCLC/Neuroendocrine Tumors
    • Presentations: 1
    • +

      P1.07-048 - Clinical Impact of the Relationship between Post-Progression Survival and Overall Survival in Extensive Disease Small Cell Lung Cancer Patients (ID 4303)

      14:30 - 14:30  |  Author(s): H. Imai

      • Abstract

      Background:
      The effects of first-line chemotherapy on overall survival (OS) might be confounded by subsequent therapies in patients with small-cell lung cancer (SCLC). Therefore, by using individual-level data, we aimed to determine the relationships between progression-free survival (PFS) or post-progression survival (PPS) and OS after first-line chemotherapies in patients with extensive disease SCLC (ED-SCLC) treated with carboplatin plus etoposide.

      Methods:
      Between July 1998 and December 2014, we analyzed 63 cases of patients with ED-SCLC who were treated with carboplatin and etoposide as first-line chemotherapy. The relationships of PFS and PPS with OS were analyzed at the individual level.

      Results:
      Spearman rank correlation analysis and linear regression analysis showed that PPS was strongly correlated with OS (r = 0.90, p < 0.05, R[2 ]= 0.71) and PFS was moderately correlated with OS (r = 0.72, p < 0.05, R[2] = 0.62). Type of relapse (refractory/sensitive) and the number of regimens administered after disease progression after the first-line chemotherapy were both significantly associated with PPS (p < 0.05).

      Conclusion:
      PPS has a stronger relationship with OS than does PFS in ED-SCLC patients who have received first-line chemotherapy. In addition, type of relapse (refractory/sensitive) after first-line treatment and the number of additional regimens after first-line treatment are significant independent prognostic factors for PPS. These results suggest that treatments administered after first-line chemotherapy affect the OS of ED-SCLC patients treated with carboplatin plus etoposide.